GLAUKOS CORPORATION |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 99.58 USD | -1.33% |
|
+4.12% | +24.61% |
| Apr. 11 | Mizuho Securities Adjusts Price Target on Glaukos to $100 From $85, Maintains Neutral Rating | MT |
| Apr. 11 | Glaukos Insider Sold Shares Worth $6,008,359, According to a Recent SEC Filing | MT |
Financials (USD)
| Sales 2024 * | 357M | Sales 2025 * | 445M | Capitalization | 5.06B |
|---|---|---|---|---|---|
| Net income 2024 * | -113M | Net income 2025 * | -74M | EV / Sales 2024 * | 14.7 x |
| Net Debt 2024 * | 176M | Net Debt 2025 * | 146M | EV / Sales 2025 * | 11.7 x |
| P/E ratio 2024 * |
-42.9
x | P/E ratio 2025 * |
-64.4
x | Employees | 907 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.44% |
More Fundamentals
* Assessed data
More news
Latest transcript on Glaukos Corporation
More recommendations
More press releases
| 1 day | -0.17% | ||
| 1 week | +4.17% | ||
| Current month | +7.04% | ||
| 1 month | +14.59% | ||
| 3 months | +9.67% | ||
| 6 months | +51.07% | ||
| Current year | +26.97% |
1 week
94.16
103.66
1 month
87.59103.66
Current year
74.75103.66
1 year
45.38103.66
3 years
33.33103.66
5 years
23.31103.66
10 years
14.25103.66
| Managers | Title | Age | Since |
|---|---|---|---|
Thomas Burns
CEO | Chief Executive Officer | 63 | 00-12-31 |
Alex Thurman
DFI | Director of Finance/CFO | 54 | 16-06-30 |
Joseph Gilliam
PSD | President | 48 | 17-05-04 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gilbert Kliman
BRD | Director/Board Member | 65 | 06-12-31 |
| Director/Board Member | 69 | 14-06-30 | |
Aimee Weisner
BRD | Director/Board Member | 55 | 14-06-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.12% | 509 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 99.19 | -1.72% | 123 848 |
| 24-04-24 | 100.9 | -0.17% | 521,714 |
| 24-04-23 | 101.1 | +2.17% | 351,098 |
| 24-04-22 | 98.95 | +2.54% | 363,654 |
| 24-04-19 | 96.5 | +1.44% | 697,810 |
Delayed Quote Nyse, April 24, 2024 at 04:00 pm EDT
More quotes
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. It develops novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders and retinal disease. Its product candidates include Micro-Invasive Glaucoma Surgery products that involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma and procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time. Its products include transdermal pharmaceuticals that are applied to the eyelid and designed to treat glaucoma, dry eye, presbyopia and other ocular surface diseases and disorders and micro-invasive, bio-erodible sustained release drug delivery implants to improve the vision of patients.
Calendar
2024-05-01
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
100.9
USD
Average target price
106.6
USD
Spread / Average Target
+5.66%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +26.97% | 5.06B | |
| +12.49% | 128B | |
| -8.82% | 10.66B | |
| -2.20% | 8.55B | |
| +15.12% | 7.1B | |
| +7.09% | 3.4B | |
| +0.27% | 3.08B | |
| -10.28% | 2.11B | |
| -8.61% | 2.03B | |
| -27.27% | 1.69B |
- Stock Market
- Equities
- GKOS Stock
